Triamcinolone

Generic Name: Triamcinolone

Brand Names: Allernaze, Aristocort, Aristocort R, Juulissa Pharmapak, Kenalog, Kourzeq, Marcaine, Nasacort, Oracort, Oralone, Pediaderm Ta, Triaderm, Trianex, Triderm, Triesence, Triloan Suik, Tritocin, Viaderm Kc, Xipere, Zilretta

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₇FO_₆

CAS Number: 124-94-7

Unique Ingredient Identifier: 1ZK20VI6TY

Background: Triamcinolone is a corticosteroid used to treat various inflammatory conditions in the body from allergic rhinitis to acute exacerbations of multiple sclerosis. Triamcinolone can be used as a one time adjunct treatment of osteoarthritic knee pain, or first line as a topical treatment of corticosteroid responsive dermatoses. Triamcinolone is more commonly see...

Indication: 肾上腺皮质激素类药。主要用于过敏性与自身免疫性炎症性疾病。由于本品潴钠作用较弱，故一般不用作肾上腺皮质功能减退的替代治疗。

Associated Conditions: Acne, Acne Vulgaris, Acute Gouty Arthritis, Allergic Contact Dermatitis, Allergic Rhinitis (AR), Allergic Skin Reaction, Alopecia Areata (AA), Ankylosing Spondylitis (AS), Aphthous Stomatitis, Asthma, Atopic Dermatitis, Autoimmune Hemolytic Anemia, Berylliosis, Bullous dermatitis herpetiformis, Chronic Eczema, Chronic Inflammatory Skin Diseases, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Contact Dermatitis, Crohn's Disease (CD), Dental Cavity, Dermatitis, Dermatomyositis (DM), Diaper Rash, Discoid Lupus Erythematosus (DLE), Edema of the cerebrum, Epicondylitis, Erythroderma, Fungal Infections, Fungal infectious disorders of the Beard, Fungal skin infection, Gingivitis, Haemorrhoids, Hemangiomas, Hypercalcemia, Inflammation of Mouth, Intertrigo, Itching of the Anus, Itching of the External Genitalia, Itching of the Foot, Itching of the genitals, Itching of the hand, Juvenile Idiopathic Arthritis (JIA), Keloids Scars, Leukemias, Lichen Planus (LP), Lichen simplex chronicus, Lymphoma, Macular Edema, Mycosis Fungoides (MF), Mycotic Eczema, Necrobiosis lipoidica diabeticorum, Neurodermatitis, Nummular Dermatitis, Ocular Inflammation, Ophthalmia, Sympathetic, Oral Erosive Lichen Planus, Otitis Externa, Pemphigus, Pericarditis, Polymyositis, Postherpetic Neuralgia, Primary adrenocortical insufficiency, Proteinuria, Psoriasis Vulgaris (Plaque Psoriasis), Psoriatic Arthritis, Psoriatic plaque, Pure Red Cell Aplasia, Purulent Wounds, Pyoderma caused by susceptible bacteria, Regional Enteritis, Rheumatoid Arthritis, Ringworm Folliculitis, Seborrheic Dermatitis, Seborrheic Dermatitis, Eczematous, Secondary Impetiginization, Secondary adrenocortical insufficiency, Secondary thrombocytopenia, Serum Sickness, Skin chapped, Stomatitis, Denture, Synovitis, Systemic Lupus Erythematosus, Temporal Arteritis, Tinea Corporis, Transfusion Reactions, Trichinosis, Tuberculosis (TB), Ulcerative Colitis, Urticaria, Uveitis, Wound Infections, Acute Bursitis, Acute Multiple sclerosis, Acute Rheumatic heart disease, unspecified, Acute Tenosynovitis, Corticosteroid-responsive dermatoses, Cutaneous candidiasis, Cystic tumour of the ganglia, Exfoliative erythroderma, Granuloma annulare lesions, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Oral infections, Oral lesions, Severe Erythema multiforme, Subacute Dermatitis, Eczematous, Symptomatic Sarcoidosis, Ulceration of the mouth, Ulcerative stomatitis

Associated Therapies: -

Clinical Trials

Evaluation of the Effect of Adding Corticosteroid to Viscosupplementation

Phase 4

Completed

Conditions: Osteoarthritis

Interventions: Drug: Hylan GF-20 alone
Drug: Triamcinolone

First Posted Date: 2011-04-14

Last Posted Date: 2014-12-23

Lead Sponsor: University of Sao Paulo General Hospital

Target Recruit Count: 108

Registration Number: NCT01335321

Locations: 🇧🇷
Instituto de Ortopedia e Traumatologia do Hospital das Clínicas da Universidade de São Paulo, São Paulo, Brazil

Keloid Scarring: Treatment and Pathophysiology

Phase 4

Withdrawn

Conditions: Keloid Scar

Interventions: Radiation: radiotherapy
Drug: 5- fluorouracil
Drug: Triamcinolone

First Posted Date: 2011-02-14

Last Posted Date: 2023-09-18

Lead Sponsor: Queen Mary University of London

Registration Number: NCT01295099

Locations: 🇬🇧
Barts and the London NHS Trust, London, UK, United Kingdom

Local Triamcinolone Injection in Active Thyroid Orbitopathy

Not Applicable

Conditions: Thyroid Disease

Interventions: Drug: Triamcinolone

First Posted Date: 2011-01-20

Last Posted Date: 2011-01-20

Lead Sponsor: HaEmek Medical Center, Israel

Target Recruit Count: 30

Registration Number: NCT01280214

Sub-tenon Triamcinolone Acetonide in Age-Related Macular Degeneration as Adjunct to Ranibizumab

Phase 2

Conditions: Wet Macular Degeneration

Interventions: Drug: Ranibizumab
Drug: Triamcinolone Acetonide

First Posted Date: 2010-11-30

Last Posted Date: 2011-02-09

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 30

Registration Number: NCT01249937

Locations: 🇨🇦
University Health Network-Toronto Western Hospital, Toronto, Ontario, Canada

The Efficacy and Safety of Different Concentrations of Localized Injections of Steroids in the Treatment of Alopecia Areata

Not Applicable

Completed

Conditions: Alopecia Areata

Interventions: Other: Normal saline
Drug: Triamcinolone acetonide

First Posted Date: 2010-11-23

Last Posted Date: 2015-06-08

Lead Sponsor: University of British Columbia

Target Recruit Count: 5

Registration Number: NCT01246284

Locations: 🇨🇦
The Skin Care Center, Vancouver General Hospital, 835 West 10th Ave, Vancouver, British Columbia, Canada

Effect of Steroid Injections in a Knee With Osteoarthritis

Phase 4

Completed

Conditions: Osteoarthritis (OA) of the Knee

Interventions: Drug: 0.9% Sodium Chloride Injection as Placebo
Drug: Triamcinolone Acetonide

First Posted Date: 2010-10-29

Last Posted Date: 2017-07-31

Lead Sponsor: Tufts Medical Center

Target Recruit Count: 140

Registration Number: NCT01230424

Locations: 🇺🇸
Tufts Medical Center, Boston, Massachusetts, United States
🇺🇸
Tufts Medical Center / Division of Rheumatology, Boston, Massachusetts, United States

Treatment of Early Nasal Polyposis With Topical Triamcinolone

Phase 1

Terminated

Conditions: Nasal Polyps

Interventions: Drug: Saline soaked sponge
Drug: Triamcinolone

First Posted Date: 2010-10-18

Last Posted Date: 2018-06-28

Lead Sponsor: Steward St. Elizabeth's Medical Center of Boston, Inc.

Target Recruit Count: 1

Registration Number: NCT01222871

Locations: 🇺🇸
St. Elizabeth's Medical Center, 736 Cambridge St, Brighton, Massachusetts, United States

Intravitreal Bevasizumab Versus Intravitreal Triamcinolone in Central Retinal Vein Occlusion (CRVO)

Phase 2

Conditions: Central Retinal Vein Occlusion

Interventions: Drug: Triamcinolone Acetonide
Drug: Bevasizumab

First Posted Date: 2010-08-10

Last Posted Date: 2010-08-10

Lead Sponsor: Shahid Beheshti University of Medical Sciences

Registration Number: NCT01178697

Locations: 🇮🇷
Imam Hossein medical center, Tehran, Iran, Islamic Republic of

Efficacy, Safety and Tolerability of Repeated Dosis of Intravitreous Bevacizumab in Uveitic Macular Oedema

Phase 3

Terminated

Conditions: Uveitis

Interventions: Drug: triamcinolone acetonide
Drug: bevacizumab

First Posted Date: 2010-03-30

Last Posted Date: 2012-03-23

Lead Sponsor: Hospital Clinic of Barcelona

Target Recruit Count: 5

Registration Number: NCT01095809

Locations: 🇪🇸
Hospital de Son Dureta, palma de Mallorca, Spain/ Baleares, Spain
🇪🇸
Hospital Santa creu i Sant Pau, Barcelona, Spain/ catalonia, Spain
🇪🇸
Instituto Vissum Alicante, Alicante, Spain/ Com. Valenciana, Spain

and more 2 locations

Intravitreal Bevasizumab Versus Intravitreal Triamcinolone in Branch Retinal Vein Occlusion

Phase 2

Conditions: Branch Retinal Vein Occlusion

Interventions: Drug: Bevacizumab
Drug: Triamcinolone Acetonide

First Posted Date: 2010-01-07

Last Posted Date: 2010-01-07

Lead Sponsor: Shahid Beheshti University of Medical Sciences

Target Recruit Count: 90

Registration Number: NCT01044329

Locations: 🇮🇷
Imam Hossein medical center, Tehran, Iran, Islamic Republic of

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy